<DOC>
	<DOCNO>NCT00276705</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , cisplatin doxorubicin , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . Thalidomide may stop growth liver cancer block blood flow tumor . Chemoembolization kill tumor cell block blood flow tumor keep chemotherapy drug near tumor . Giving combination chemotherapy , thalidomide , chemoembolization surgery may make tumor small reduce amount normal tissue need remove . Giving thalidomide together chemotherapy surgery may kill remain tumor cell prevent tumor come back . PURPOSE : This phase II trial study well give combination chemotherapy thalidomide together chemoembolization work treat young patient undergo surgery newly diagnose liver cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Thalidomide Treating Younger Patients Undergoing Surgery For Newly Diagnosed Liver Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine event-free overall survival younger patient undergo surgery newly diagnose , noncirrhotic hepatocellular carcinoma ( HCC ) treat neoadjuvant cisplatin , doxorubicin hydrochloride , thalidomide ( PLADOTH ) follow transarterial hepatic arterial chemoembolization comprise cisplatin doxorubicin hydrochloride adjuvant cyclophosphamide thalidomide . - Determine efficacy tolerability PLADOTH patient initially unresectable noncirrhotic HCC treat regimen . - Determine rate complete surgical resection encouragement liver transplantation treatment strategy valid option tumor removal partial liver resection surgical option remain unfeasible patient treat regimen . - Determine long-term remission decrease relapse rate patient treat regimen base postoperative regimen . Secondary - Determine response rate patient treat regimen treatment PLADOTH . - Determine short-term toxicity feasibility PLADOTH patient treat regimen . - Determine efficacy toxicity postoperative regimen term maintenance duration complete remission ( evidence disease normal alpha-fetoprotein , initially elevate ) patient treat regimen . - Determine whether response PLADOTH RECIST criterion use well monitor response patient treat regimen . - Determine whether rate fall serum VEGF bFGF level PLADOTH use prognostic factor short-term long-term outcome patient treat regimen . - Determine feasibility chemoembolization patient treat regimen respond PLADOTH . - Determine subset tumor may benefit angiostatic treatment approach base radiological , surgical , pathological data collect patient treated regimen . - Identify possible novel factor might influence treatment choice disease outcome base radiological , surgical , pathological data collect patient treated regimen . - Determine guideline diagnostic , therapeutic , follow-up management would improve clinical care patient treat regimen . OUTLINE : This multicenter , nonrandomized , open-label study . All patient undergo either tumor biopsy resection . Patients localize resectable tumor undergo resection . They proceed directly postoperative treatment . Patients initially unresectable tumor undergo biopsy proceed pre-operative regimen . - Pre-operative chemotherapy thalidomide ( PLADOTH ) : Patients receive PLADOTH comprise cisplatin IV continuously 24 hour day 1 , doxorubicin hydrochloride IV 1 hour day 1 2 ( IV continuously 24 hour day 1 3 ) , oral thalidomide daily day 1-21 . Treatment repeat every 21 day 4 course absence disease progression unacceptable toxicity . Patients whose tumor deem resectable proceed surgery . Patients respond disease whose tumor remain unresectable proceed chemoembolization receive 2 additional course PLADOTH . - Transarterial hepatic artery chemoembolization ( TACE ) : Patients undergo TACE comprise cisplatin doxorubicin hydrochloride administer catheter place near tumor . TACE may repeat every 3-4 week long disease continue respond tumor become resectable . Patients also receive oral thalidomide daily TACE . Once tumor deem resectable , patient proceed surgery . - Surgery : Patients undergo surgical resection tumor . Patients undergo either partial total hepatectomy follow liver transplant lung surgery , necessary . Patients proceed postoperative treatment . - Postoperative treatment : Beginning within 6 week surgery , patient receive oral cyclophosphamide every day oral thalidomide daily 1 year absence disease progression unacceptable toxicity . Patients metastatic disease show disease progression time treatment go study receive individual advice regard treatment base decision principal investigator . After completion study treatment , patient follow periodically 5 year . PROJECTED ACCRUAL : A total 47 patient accrue study .</detailed_description>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm hepatocellular carcinoma ( HCC ) family tumor percutaneous needle biopsy ( unless primary tumor resection attempt ) Newly diagnose disease No recurrent disease Fibrolamellar transitional variant Noncirrhotic disease If suspicious liver cirrhosis ( e.g. , abnormal liver function test and/or positive viral serology and/or radiological evidence ) diagnosis , patient must undergo biopsy normal liver exclude liver cirrhosis PATIENT CHARACTERISTICS : Able follow protocol Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Life expectancy least 3 month Glomerular filtration rate ≥ 7550 % low limit normal age ( ≥ 60 mL/min patient ≥ 2 year old ) Cardiac ejection fraction ≥ 29 % baseline ECHO PRIOR CONCURRENT THERAPY : No prior treatment HCC</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>29 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>adult primary hepatocellular carcinoma</keyword>
	<keyword>childhood hepatocellular carcinoma</keyword>
	<keyword>advanced adult primary liver cancer</keyword>
	<keyword>localize resectable adult primary liver cancer</keyword>
	<keyword>localize unresectable adult primary liver cancer</keyword>
	<keyword>stage I childhood liver cancer</keyword>
	<keyword>stage II childhood liver cancer</keyword>
	<keyword>stage III childhood liver cancer</keyword>
	<keyword>stage IV childhood liver cancer</keyword>
</DOC>